Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 1.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 743,795 shares of the company’s stock after purchasing an additional 11,579 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Annexon were worth $3,816,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC increased its holdings in shares of Annexon by 3.2% in the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after acquiring an additional 262,229 shares during the period. State Street Corp grew its position in Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after purchasing an additional 2,068,294 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Annexon by 18.3% in the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock valued at $12,693,000 after purchasing an additional 331,269 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Annexon by 16.0% during the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock valued at $10,101,000 after buying an additional 235,810 shares during the last quarter. Finally, Sio Capital Management LLC bought a new stake in shares of Annexon during the third quarter valued at approximately $8,484,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Price Performance

Annexon stock opened at $2.29 on Thursday. Annexon, Inc. has a 12-month low of $2.28 and a 12-month high of $8.40. The stock has a market capitalization of $251.24 million, a PE ratio of -2.18 and a beta of 1.14. The firm has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $5.03.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). On average, analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.